HIGHLIGHTS OF PRESCRIBING INFORMATIONThese highlights do not include all the information needed to use CYKLOKAPRON safely and effectively. See full prescribing information for CYKLOKAPRON. CYKLOKAPRON® (tranexamic acid) injection, for intravenous use Initial U.S. Approval: 1986 RECENT MAJOR CHANGES
INDICATIONS AND USAGECYKLOKAPRON is an antifibrinolytic indicated in patients with hemophilia for short-term use (2 to 8 days) to reduce or prevent hemorrhage and reduce the need for replacement therapy during and following tooth extraction. (1) DOSAGE AND ADMINISTRATION
DOSAGE FORMS AND STRENGTHSCONTRAINDICATIONSWARNINGS AND PRECAUTIONS
ADVERSE REACTIONSMost common adverse reactions are nausea, vomiting, diarrhea, allergic dermatitis, giddiness, hypotension, and thromboembolic events. (6) To report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc. at 1-800-438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. DRUG INTERACTIONSSee 17 for PATIENT COUNSELING INFORMATION. Revised: 3/2021 |

If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.
CYKLOKAPRON® Highlights (tranexamic acid)
To report an adverse event related to a Pfizer product and you are not part of a clinical trial* for this product, click the link below to submit your information: Pfizer Safety Reporting Site
*If you are involved in a clinical trial for either product, adverse events should be reported to your coordinating study site.
If you cannot use the above website to report an adverse event related to a Pfizer product, please call Pfizer Medical Information at (800) 438-1985.
(800)-332-1088.